文献速递慢性肾脏病

儿童CKD患者基层医疗中潜在肾毒性药物处方率研究

Primary Care Prescriptions of Potentially Nephrotoxic Medications in Children with CKD.
PubMed 文献 · Clin J Am Soc Nephrol · 2019-12-12

本研究基于英国CPRD数据库1997至2017年数据,匹配分析1018例新发CKD儿童与4072例无CKD儿童,发现CKD患儿潜在肾毒性药物处方率为71/100人年,显著高于无CKD患儿的8/100人年(调整率比4.1,95%CI 2.7-6.1)。

要点

  • 儿童CKD患者潜在肾毒性药物处方率显著高于无CKD儿童。
  • 26%的CKD患儿随访期间至少被处方一种潜在肾毒性药物。
  • 需关注基层医疗中儿童CKD患者的肾毒性药物暴露问题。

核心结论

  • 儿童CKD患者被处方潜在肾毒性药物的比率很高。

研究设计与样本

  • 回顾性匹配人群队列研究,纳入英国CPRD数据库中1997至2017年注册的18岁以下患者。
  • 1018例新发CKD患儿与4072例无CKD儿童按1:4匹配,匹配因素包括诊断日期、性别、年龄、诊所及入组前一年就诊次数。

主要发现

  • CKD患儿中26%被处方至少一种潜在肾毒性药物,无CKD儿童为15%。
  • CKD患儿潜在肾毒性药物处方率为71/100人年(95%CI 55-93),无CKD儿童为8/100人年(95%CI 7-9)。
  • 调整率比为4.1(95%CI 2.7-6.1),CKD患儿处方率显著更高。

关键数值与推荐

  • 主要分析药物类别包括氨基糖苷类、抗病毒药、非甾体抗炎药、水杨酸盐、质子泵抑制剂和免疫调节剂。
  • 次要分析采用扩展肾毒性定义,额外包括血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂等。

临床怎么用

  • 基层医生为儿童CKD患者处方药物时需警惕潜在肾毒性药物。
  • 应加强儿童CKD患者用药审核,减少可避免的肾毒性药物暴露。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Pediatric CKD management focuses on limiting kidney injury, including avoiding nephrotoxic medications. Nephrotoxic medication prescription practices for children with CKD are unknown. Our objective was to determine the prevalence and rates of primary care prescriptions for potentially nephrotoxic medications in children with CKD versus without CKD. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We conducted a retrospective, matched population-based cohort study of patients aged <18 years, registered at a general practice participating in the UK Clinical Practice Research Datalink (CPRD) from 1997 to 2017. Children with a clinical code indicating an incident diagnosis of CKD were matched 1:4 to patients without CKD on CKD diagnosis date, sex, age, CPRD practice, and number of general practitioner visits in the year before cohort entry. We calculated the prevalence and the rate of potentially nephrotoxic medication prescriptions throughout the follow-up period in patients with versus without CKD. Primary analyses included the following medication classes: aminoglycosides, antivirals, nonsteroidal anti-inflammatory drugs, salicylates, proton pump inhibitors, and immunomodulators. Secondary analyses used an expanded nephrotoxicity definition that also included, among others, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Adjusted prescription rates were calculated using multivariable binomial regression. RESULTS: From 1,535,816 eligible patients, we identified 1018 incident CKD and 4072 non-CKD matches (mean age, 9.8 years [range, 1.1-17.9 years]; 52% male; mean follow-up time, 3.3 years). Overall, 26% of patients with and 15% of patients without CKD were prescribed one or more potentially nephrotoxic medication during follow-up. The overall rate of nephrotoxic medication prescriptions was 71 (95% confidence interval [95% CI], 55 to 93) prescriptions per 100 person-years in patients with CKD and eight (95% CI, 7 to 9) prescriptions per 100 person-years in patients without CKD (adjusted rate ratio, 4.1; 95% CI, 2.7 to 6.1). CONCLUSIONS: Potentially nephrotoxic medications are prescribed at high rates to children with CKD.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Lefebvre CE, Filion KB, Reynier P, et al. Primary Care Prescriptions of Potentially Nephrotoxic Medications in Children with CKD. Clin J Am Soc Nephrol. 2019. PMID: 31831578. doi:10.2215/CJN.03550319

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。